Leads Biolabs focus on innovation, leveraging our robust in-house R&D capabilities, we are committed to exploring novel mechanisms of action and translating fundamental biological research into a rich asset portfolio. We continue to invest in fundamental biological research and translational medicine capabilities, enriching our pipeline with innovative therapies and positioning us at the forefront of technology and market trends. We are also committed to enhancing our collaborations with KOLs, top hospitals and academic institutions, in China and globally, to translate our scientific achievements into potential commercial success. The company actively develops mutually beneficial and win-win business cooperation with large multinational or domestic pharmaceutical companies and research institutes, including but not limited to the following:
Exclusive License
Entered into a license and collaboration agreement with BeiGene, under which we granted to BeiGene an exclusive license to develop, manufacture and commercialize LBL-007 outside Greater China, LBL-007's advanced position in global clinical trials has been further consolidated.
Collaborative Development
Entered into a strategic collaborative development agreement with BiOneCure, a collaboration that combines our capabilities with BiOneCure’s proprietary ADC payload-linker platforms and related know-how, potentially accelerating the path to clinical trials and subsequent commercialization.
Global Partner
Cooperation for providing patients with better treatment options
